Keyword: Vertex Pharmaceuticals
Vertex's newly expanded site covers 170,000 square feet, boosting Vertex’s ability to hunt for the next generation of blockbusters.
Shares in CRISPR fell 15% as investors digested the delay to the start of the gene-editing startup’s first U.S. clinical trial.
Vertex says its long-acting version of Kalydeco has been held up by an FDA data request—but analysts think it could be a bigger issue for its rivals.
Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.
The first trial of Translate Bio's nebulized messenger RNA therapy is now due to start in mid-2018, with results due a year later.
The financing tees up Enterprise to take three projects into the clinic and push one of them through a midphase proof-of-concept trial.
Gilead’s director of oncology clinical research jumps to Compugen, longtime Teva exec becomes Dr. Reddy's COO, Astellas names new ethics & compliance head.
Meyers retires as Gilead's commercial head, Kewalramani was promoted to Vertex's CMO, Recipharm CFO Stenqvist jumped ship to Sobi.
Reshma Kewalramani, M.D., has been promoted to CMO and EVP of global medicines development and medical affairs at Vertex.
CRISPR is a promising treatment for blood disorders, but it comes with challenges, such as off-target effects.